Alligator Bioscience
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
ATORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000767188 (+8 more)
- LEI:
- 549300E15VI0MB7LXV19
- Country:
- Sweden
- Address:
- C/O Medicon Village, 223 81 Lund
- Sector:
- Manufacturing
Description
Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-02-12 08:00 | English | 2.4 MB | |||
| 2019-12-17 13:00 |
Alligator Bioscience: Första patienten doserad med ATOR-1017 som utvecklas för …
|
Swedish | 75.9 KB | ||
| 2019-12-17 13:00 |
Alligator Bioscience: First patient dosed with ATOR-1017 developed for metastas…
|
English | 94.7 KB | ||
| 2019-12-11 17:30 |
Per-Olof Schrewelius lämnar rollen som CFO på Alligator Bioscience
|
Swedish | 80.1 KB | ||
| 2019-12-11 17:30 |
CFO Per-Olof Schrewelius leaves Alligator Bioscience
|
English | 94.0 KB | ||
| 2019-12-09 13:55 | English | 33.8 KB | |||
| 2019-11-29 08:30 |
Alligator Bioscience AB utser Chief Operating Officer
|
Swedish | 81.9 KB | ||
| 2019-11-29 08:30 |
Alligator Bioscience AB appoints Chief Operating Officer
|
English | 81.3 KB | ||
| 2019-11-13 10:30 |
Valberedning utsedd inför årsstämma 2020 i Alligator Bioscience AB
|
Swedish | 88.5 KB | ||
| 2019-11-13 10:30 |
Nomination Committee appointed in respect of AGM 2020 in Alligator Bioscience AB
|
English | 90.4 KB | ||
| 2019-11-08 15:00 |
Aptevo Therapeutics och Alligator Bioscience presenterar nya prekliniska data f…
|
Swedish | 121.9 KB | ||
| 2019-11-08 15:00 |
Aptevo Therapeutics and Alligator Bioscience present new preclinical data for A…
|
English | 129.0 KB | ||
| 2019-11-06 14:00 |
Alligator Bioscience: ATOR-1017 skapar långvarig immunitet – nya prekliniska da…
|
Swedish | 82.6 KB | ||
| 2019-11-06 14:00 |
Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity – New Preclinical…
|
English | 100.3 KB | ||
| 2019-10-24 08:00 | Swedish | 3.2 MB |
Automate Your Workflow. Get a real-time feed of all Alligator Bioscience filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alligator Bioscience
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alligator Bioscience via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-28 | Peter Ostler | Other | Sell | 1,658,134 | 179,045.31 SEK |
| 2024-04-11 | Staffan Encrantz | Other | Sell | 44,108,581 | 47,196,181.67 SEK |
| 2022-10-27 | Sören Bregenholt Frederiksen | Other | Buy | 52,000 | 72,748.00 SEK |
| 2022-10-25 | Marie Svensson | Other | Buy | 12,000 | 16,632.00 SEK |
| 2022-08-19 | Sören Bregenholt Frederiksen | Other | Buy | 13,906 | 25,726.10 SEK |
| 2022-08-18 | Sören Bregenholt Frederiksen | Other | Buy | 31,094 | 56,911.35 SEK |
| 2022-05-31 | Peter Ostler | Other | Buy | 100,000 | 151,500.00 SEK |
| 2022-05-04 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,895.00 SEK |
| 2022-05-02 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,811.00 SEK |
| 2022-04-30 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 51,171.00 SEK |
Peer Companies
